A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS
7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS)Location: Paris, FRANCEDate: OCT 25-28, 2017, Paris, Fransa, 25 - 28 Ekim 2017, cilt.23, ss.395-397, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Cilt numarası: 23
- Basıldığı Şehir: Paris
- Basıldığı Ülke: Fransa
- Sayfa Sayıları: ss.395-397
- Ondokuz Mayıs Üniversitesi Adresli: Evet